Sep 20, 2022
Vancouver, Canada, and Uttenweiler, Germany (September 20, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...
Feb 22, 2022
Vancouver, Canada, and Uttenweiler, Germany (February 22, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...
Jun 8, 2021
Research and development lab set up, preliminary mescaline synthesis completeModified synthesis process developed, mescaline batches manufacturedDevelopment of analytical methods and validation, GMP standard operating procedures...
Feb 10, 2021
Vancouver, Canada (February 10, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce that XPhyto Laboratories...
Feb 3, 2021
Vancouver, Canada (February 3, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce that XPhyto Laboratories...
Nov 9, 2020
Psilocybin, mescaline, LSD, MDMA, DMT and other psychedelic compounds added to exclusive dealing agreement for the development of psychedelic-based therapeutics Vancouver, Canada (November 09, 2020)...
Nov 3, 2020
Research agreement to investigate the feasibility of a proprietary biotechnology process for the industrial production of psilocybin APIPsilocybin is designated by the FDA as a...
May 12, 2020
Vancouver, Canada (May 12, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / FSE:4XT / OTC:XPHYF) (“XPhyto” or the “Company”) is pleased to announce that it has...
Hear about our latest research, products, exclusive partnerships & more.